Key Insights

Highlights

Success Rate

67% trial completion

Treatment Research

4 treatments under study, led by Bortezomib

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 54/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

66.7%

-19.9% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results67% success

Data Visualizations

Phase Distribution

3Total
Phase 2 (2)
Phase 3 (1)

Trial Status

Completed2
Terminated1

Trial Success Rate

66.7%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT00210353Phase 3CompletedPrimary

Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma

NCT00210392Phase 2TerminatedPrimary

VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy

NCT00210327Phase 2CompletedPrimary

VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy

Showing all 3 trials

Research Network

Common Treatments

  • Bortezomib2
  • Rituximabchlorambucil1
  • Chlorambucil1
  • Rituximab1

Active Sponsors

  • International Extranodal Lymphoma Study Group (IELSG)3

Top Investigators

Activity Timeline